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ABSTRACT
Celiac disease is a multisystem autoimmune disorder, which is induced by dietary gluten exposure. This 
disease usually found in European population, but with the increase of Asian population tendency to eat western 
style, which contain gluten, celiac disease frequency is expected to increase in Asian population for the near 
IXWXUH7KH¿QGLQJRIGLDJQRVWLFPRGDOLWLHVZKLFKLVKLJKO\VHQVLWLYHDQGVSHFL¿FVWDUWLQJZLWKWKHDQWLJOLDGLQ
and then the antiendomysium and anti-transglutaminase antibodies, has increased the awareness of clinicians 
DQGSDWLHQWVWRZDUGVWKLVFRQGLWLRQ7KHXQGHUVWDQGLQJRIGH¿QLWLRQSDWKRJHQHVLVGLDJQRVWLFSURFHGXUHDQG
current management of celiac disease is needed to avoid morbidity and mortality of this disease.
Keywords: Celiac disease, autoimmune disorder, dietary gluten 
ABSTRAK
Penyakit celiac adalah gangguan autoimun yang bersifat multisistem, yang dicetuskan oleh paparan terhadap 
gluten dalam diet. Penyakit ini dahulu banyak ditemukan pada populasi Eropa, namun seiring meningkatnya 
kecenderungan masyarakat Asia untuk mengadopsi pola makan dari negara barat yang banyak mengandung 
gluten diperkirakan kejadian penyakit ini akan meningkat pada populasi Asia ke depannya. Munculnya modalitas 
SHPHULNVDDQ\DQJVDQJDWVHQVLWLIGDQVSHVL¿NPXODLDZDOQ\DGDULGLWHPXNDQQ\DDQWLJOLDGLQGDQNHPXGLDQ
antiendomysium dan antibody anti-transglutaminase telah meningkatkan kepedulian klinisi dan juga para 
SDVLHQDNDQSHQ\DNLWLQL3HPDKDPDQDNDQGH¿QLVLSDWRJHQHVLVFDUDGLDJQRVLVGDQSHQDQJDQDQWHUNLQLGDUL
penyakit ini perlu dipahami oleh para dokter agar dapat menghindari morbiditas dan mortalitas yang terkait 
dengan penyakit ini.
Kata kunci: penyakit celiac, penyakit autoimun, diet gluten 
INTRODUCTION
Celiac disease (CD) is a multisystem autoimmune 
disorder precipitated by exposure to dietary gluten 
in genetically predisposed individuals.1–8 In the past, 
this condition was considered a rare disorder, mostly 
affecting individuals of European origin, with onset 
GXULQJWKH¿UVW\HDUVRIOLIH$IWHUWKHHPHUJHQFHRI
KLJKO\VHQVLWLYHDQGVSHFL¿FVHURORJLFDOWRROVVWXGLHV
have shown that CD is one of the commonest, lifelong 
disorders affecting mankind all over the world. Many 
developing countries in Asia including Indonesia are 
likely to have increasing incident of celiac disease in 
the near future given the diffuse tendency to adopt 
Western, gluten-rich dietary patterns.4 
The diagnosis of CD can be challenging because 
the clinical spectrum of the disease varies, and some 
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individuals present with mild symptoms. Many new 
diagnoses now are made from screening high risk 
individuals. The common feature among these at-
risk groups is that they carry the alleles encoding 
HLA-DQ2 or HLA-DQ8.7 CD causes enteropathy 
of the small intestine, resulting in poor absorption 
of nutrients leading to malabsorption with its own 
concequences.1,2,5,7,9 
This disease contribute substantially to childhood 
morbidity and mortality in many developing countries, 
hence a timely diagnosis and give the best management 
to avoid morbidity and mortality of this disease. 
DEFINITION
*OXWHQFDQEHGH¿QHGDVWKHUXEEHU\SURWHLQPDVV
that remains when wheat dough is washed to remove 
starch. The major protein components of gluten, gliadins 
and glutenins, are storage proteins in wheat. Gluten and 
gluten-related proteins are present in wheat, rye, and 
barley, and are used widely in food processing to give 
GRXJKWKHGHVLUHGEDNLQJSURSHUWLHVDGGÀDYRUVDQG
improve texture.5,9 Celiac disease (CD) is a chronic, 
multiple-organ autoimmune disease that affects the small 
intestine in genetically predisposed children and adults. 
It is precipitated by the ingestion of gluten-containing 
food. It may also be referred to as celiac sprue, gluten-
sensitive enteropathy, or nontropical sprue.1–8
(3,'(0,2/2*<
Early epidemiological studies regarded celiac 
disease as a disease of individuals of Caucasian 
ancestry, located mainly in Europe and North 
America. However, further studies in other areas 
of the world revealed a similar prevalence of celiac 
disease there. The prevalence of the disorder is 
globally 1%, but wide variations between countries 
have been shown.5 Meta-analysis conducted by Singh 
et al. found that CD is not uncommon in Asia and 
the sero-prevalence and prevalence of CD in Asia 
is 1.6% and 0.5%, respectively.6 Children with type 
1 diabetes, Down’s syndrome, autoimmune thyroid 
disease, Turner syndrome, William’s syndrome, IgA 
GH¿FLHQF\DXWRLPPXQH OLYHUGLVHDVHDQGKDYH¿UVW
degree relatives with CD has increased prevalence in 
developing this disease.2
*(1(7,&6$1' 3$7+2*(1(6,6 2) &(/,$&
DISEASE (CD)
&HOLDFGLVHDVH LV FKDUDFWHUL]HGE\ LQÀDPPDWRU\
mediated atrophy of the villi that protrude from the 
mucosa of the small intestine. The major environmental 
antigen associated with CD is gliadin, a protein found 
in wheat. The genetic predisposition is linked to the 
SUHVHQFHRIFHUWDLQFODVV,,+/$DOOHOHVVSHFL¿FDOO\
HLA-DQ2 and HLA-DQ8.5,8,9 Wheat gluten is 
FRPSRVHG RI JOLDGLQV DQG JOXWHQLQV7KH ĮJOLDGLQ
proteins have some unique characteristics, including 
large numbers of proline and glutamine residues. The 
prolines limit proteolytic degradation, resulting in 
the presentation of large, immunogenic peptides. The 
glutamine residues in gliadin are excellent substrates 
for the enzyme tissue transglutaminase (TTG). TTG 
deamidates select glutamines to glutamates, increasing 
the antigenicity of the peptides. The deamidated gliadin 
SHSWLGHVGHPRQVWUDWHDKLJKDI¿QLW\LQWHUDFWLRQZLWK
the peptide binding groove of the HLA-DQ2 and HLA-
DQ8 molecules. The HLA/deamidated gliadin peptide 
complex then interacts with T-cell receptors (TCRs), 
DFWLYDWLQJJOLDGLQVSHFL¿F&'7FHOOV7KHVH7FHOOV
subsequently interact with B cells, initiating production 
RIDQWLERGLHVVSHFL¿FIRUGHDPLGDWHGJOLDGLQ$FWLYDWHG
CD4+ T cells is secreting mainly Th1 cytokines such 
DV ,)1ȖZKLFK LQGXFHV WKH UHOHDVH DQG DFWLYDWLRQ
of MMPs by myofibroblasts, finally resulting in 
mucosal remodeling and villus atrophy. Additionally, 
Th2 cytokines are produced driving the production of 
(auto-) antibodies to gluten and TG2. Other cytokines 
VXFKDV ,/ ,)1ĮRU ,/ VHHP WRSOD\D UROH
in polarizing and maintaining the Th1 response. 
Furthermore, IL-15 links the adaptive immune system 
to innate immune responses. The schematic processes 
of immunological interaction in celiac disease can be 
VHHQLQ¿JXUHDQG10 
Upon stimulation with gliadin peptide p31-49 
(and other peptides), epithelial cells, macrophages, 
and dendritic cells secrete IL-15, which in turn up-
regulates both the NKG2D receptor on IELs and its 
epithelial ligand MICA. The thus stimulated cytotoxic 
lymphocytes induce increased epithelial apoptosis 
and permeability. Furthermore, the NKG2C receptor 
on a subset of natural killer–like IELs is stimulated 
by its epithelial ligand HLA-E on epithelial cells, 
resulting in their proliferation and cytotoxicity, whereas 
VWLPXODWLRQ RI Ȗį+ CD8+ IELs bearing the NKG2A 
UHFHSWRU YLD+/$( LQGXFHV7*)ȕ VHFUHWLRQ DQG
therefore a regulatory phenotype. Gliadin (cereal) 
peptides can also directly elicit innate immune 
responses in macrophages and dendritic cells via 
pattern recognition receptors such as Toll-like receptor 
4 or other MyD88-dependent pathways. This drives 
PDWXUDWLRQRIWKHVHFHOOVDQGVHFUHWLRQRILQÀDPPDWRU\
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)LJXUH3DWKRJHQHVLVRIFHOLDFGLVHDVH*OXWHQSHSWLGHVWKDW
DUHKLJKO\ UHVLVWDQW WR LQWHVWLQDOSURWHDVHVUHDFK WKH ODPLQD
SURSULD YLD HLWKHU HSLWKHOLDO WUDQVF\WRVLV RU DQ LQFUHDVHG
HSLWKHOLDO WLJKW MXQFWLRQDO SHUPHDELOLW\ &URVVOLQNLQJ DQG
SDUWLFXODUO\GHDPLGDWLRQRI JOXWHQSHSWLGHVE\7*FUHDWHV
SRWHQW LPPXQRVWLPXODWRU\ HSLWRSHV WKDW DUH SUHVHQWHG YLD
HLA-DQ2 or HLA-DQ8 on antigen-presenting cells.10
)LJXUH,QQDWHLPPXQHUHVSRQVHVLQFHOLDFGLVHDVH
F\WRNLQHVVXFKDV,/ȕ,/WXPRUQHFURVLVIDFWRUĮ
and MCP-1, which can potentiate the adaptive immune 
response to gluten. APC, antigen presenting cell; pDC, 
plasmacytoid dendritic cell.10
7DEOH:KRVKRXOGEHWHVWHGIRUFHOLDFGLVHDVH8
High Risk Patients Routinely Test for CD: 
Consider Endoscopy even if Serology 
negative
Medium Risk Patients Consider CD 
6HURORJLF7HVWLQJ&'6XI¿FLHQWO\([FOXGHG
if Serology negative
Low Risk Patients Consider testing if refractory 
to standard therapy or other clinically unusual 
IHDWXUHV &' VXI¿FLHQWO\ H[FOXGHG LI VHURORJ\
negative.
(1) Chronic gastrointestinal symptoms 
with a family history of celiac 
disease or a personal history 
of autoimmune disease or IgA 
GH¿FLHQF\
(2) Biopsy proven dermatitis 
herpetiformis 
(3) Chronic diarrhea 
(4) Failure to thrive in children 
,URQGH¿FLHQF\DQHPLDUHIUDFWRU\WR
oral supplementation
(1) Irritable bowel syndrome 
(2) Elevated liver function tests 
,URQGH¿FLHQF\DQHPLD
(4) Fatigue/lethargy 
(5) Chronic gastrointestinal symptoms 
without a family history of celiac disease 
or a personal history of autoimmune 
disease 
(6) Peripheral neuropathy 
(7) Ataxia 
(8) Dental enamel defects 
(9) Recurrent aphthous ulcerations (10) 
Hyposplenism 
(11) Fertility abnormalities 
(12) Down’s or Turner’s syndrome (13) 
.QRZQ,J$GH¿FLHQF\
(14) Microscopic colitis
(1) Osteopenia/osteoporosis 
(2) Fibromyalgia 
(3) Chronic Fatigue Syndrome 
(4) Heartburn/GERD
(5) Acute or chronic pancreatitis (6) Alopecia 
(7) Myalgias/Arthralgias 
(8) Autoimmune liver disease 
(9) Personal history of autoimmune disease or 
connective tissue disease without ongoing 
unexplained symptoms 
(10) Skin lesions other than dermatitis 
herpetiformis 
(11) Headaches including migraines 
(12) Mood disorders 
$WWHQWLRQGH¿FLWGLVRUGHUFRJQLWLYH
impairment 
(14) Epilepsy 
(15)Restless leg syndrome
6&5((1,1*2)&(/,$&',6($6(&'
The most important reason for the relatively low 
rate of CD diagnosis is failure to consider testing. CD 
is often not considered due to its wide range of clinical 
presentation. CD diagnosis rate is increasing due to both 
increased true prevalence and improved awareness of 
its variable clinical presentation. Recommendations are 
now available to help clinicians decide which patients 
should be tested for CD (Table 1).8
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',$*126,6675$7(*,(6,1&(/,$&',6($6(
The clinical manifestations of celiac disease 
are classic (signs and symptoms of malabsorption 
including diarrhea, steatorrhea, weight loss, or growth 
failure), nonclassic and symptomatic (with evident 
gastrointestinal and/or extra-intestinal symptoms), or 
asymptomatic.5,7,9  Kelly, et al summarized presents 
information about individuals who may be at increased 
risk for celiac disease and for whom the threshold for 
testing is, accordingly, lower. This can be seen in table 2.7
Four guidelines on CD diagnosis have been 
published by gastrointestinal organizations since 
2012. All guidelines include the combined use 
of biopsy and serologic analyses for diagnosis. 
According to American College of Gastroenterology 
(ACG) 2013 CD guidelines combination of both 
small intestinal biopsy and serologic tests (anti-tissue 
transglutaminase (tTG) or anti-deamidated gliadin 
peptide (DGP) are recommended for diagnosis of 
CD.11 A consensus guideline in 2016 by the European 
Society of Pediatric Gastroenterology, Hepatology 
and Nutrition (ESPGHAN) proposed a non-invasive 
method of diagnosing CD in select pediatric patients. 
The ESPGHAN algorithm suggested that, in pediatric 
7DEOH3DWLHQWVZKRPLJKWUHTXLUHWHVWLQJIRU&HOLDF'LVHDVH7
6\PSWRPVDQG6LJQV $VVRFLDWHGFRQGLWLRQV*DVWURLQWHVWLQDO Extraintestinal
Chronic diarrhea 
Chronic abdominal pain 
Malabsorption 
Bloating 
Erratic bowel habit (similar to IBS) 
Constipation (more commonly in children) 
Failure to thrive/weight loss 
Anorexia 
Vomiting 
GERD
,URQGH¿FLHQF\DQHPLD
2WKHUGH¿FLHQF\VWDWHVYLWDPLQ%YLWDPLQ'IRODWH
zinc, vitamin B6)
Fatigue 
Recurrent aphthous stomatitis 
Increased hepatic transaminase levels 
Short stature 
Delayed puberty/menarche Amenorrhea 
Early menopause 
Dermatitis herpetiformis 
Osteopenia/osteoporosis 
Dental enamel hypoplasia 
Peripheral neuropathy 
Hyposplenism
Family history of celiac disease 
Type 1 diabetes 
Autoimmune thyroid disease 
Autoimmune liver disease 
6HOHFWLYH,J$GH¿FLHQF\
Sjögren syndrome 
Down syndrome 
Turner syndrome 
Williams syndrome









Symptomatic 
patients
x Re-evaluation 
x HLA DQ2 & DQ8 
x Consider other diagnosis 
Discordant results 
Serology 
Consider other 
diagnoses
Celiac disease unlikely 
Biopsy
HLA DQ2 &DQ8 
Celiac disease 
Re-evaluation 
Potential celiac disease?
Incidental findings at 
endoscopy and histology 
+LJKULVNSRSXODWLRQV
Serology Biopsy 
x Re-evaluation 
x HLA DQ2 & DQ8 
x Consider other  
diagnosis
Serology 
-ve
+ve
+ve
+ve
+ve
+ve
+ve-ve
-ve
-ve
-ve
-ve
)LJXUH$SSURDFKWRFHOLDFGLVHDVHGLDJQRVLVFRQ¿UPLIELRSV\LVSRVLWLYH7
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patients who have symptoms consistent with CD can 
EHGLDJQRVHGZLWKRXWELRSV\FRQ¿UPDWLRQLIWKH\KDYH
an IgA tTG titer >10-fold above the upper limit of 
normal, a positive endomysial antibody (EMA) in a 
separate blood sample, and carry the HLA DQ2 or DQ8 
haplotype.2 The British Society of Gastroenterology 
recommendations for adult CD diagnosis suggest that 
serologic tests, either tTG, EMA, or DGP should be 
GRQHDVWKH¿UVWVWHSLQGLDJQRVLVIROORZHGE\VPDOO
LQWHVWLQDOELRSV\LVDGH¿QLWLYHWHVWWRGLDJQRVH&'12 
Meanwhile, recent guidelines for adult CD patients 
from the World Gastroenterological Association 
recommend serologic tests including anti-tTG and/
or anti-EMA, or anti-DGP for diagnosis and biopsy 
suggested but not considered mandatory for CD 
diagnosis which is appropriate for countries with 
limited healthcare resources.5 The guidelines overlap 
substantially with the major difference between all 
four guidelines being that ACG and BSG mandates 
intestinal biopsy to confirm the diagnosis of CD, 
while ESPGHAN and WGO allow diagnosis of CD 
without biopsy in certain conditions. Figure 3 showed 
an integrated approach to celiac disease diagnosis.7
(QGRVFRS\DQG+LVWRORJ\
We should suspect that a person has CD if the 
endoscopy finds scalloping of duodenal folds, 
¿VVXULQJRYHU WKH IROGV DQGDPRVDLFSDWWHUQ LQ WKH
PXFRVDÀDWWHQLQJRIWKHIROGVGHFUHDVLQJQXPEHURI
IROGVZLWKPD[LPXPLQVXIÀDWLRQDEVHQFHRIYLOOLDW
PDJQL¿FDWLRQDQGJUDQXODUDSSHDUDQFHRIWKHGXRGHQDO
bulb. An example of classical scalloping of duodenal 
mucosa seen in Celiac disease at endoscopy can be seen 
LQ¿JXUH8 Intestinal mucosal biopsies should always 
be obtained when any of the above endoscopic features 
are observed. Nevertheless, endoscopic biopsies should 
also be obtained even if the endoscopic folds appear 
normal, but there is a clinical suspicion of the disease, 
since many patients with celiac disease may have 
apparently normal folds. An absence of endoscopic 
¿QGLQJVKDVDORZSUHGLFWLYHYDOXHIRUGLVFDUGLQJWKH
possibility of celiac disease in low-risk populations.5
A combination of villous abnormalities seen at 
intestinal biopsies, together with a positive serological 
test, is the gold standard diagnostic criterion for 
celiac disease. A modified Marsh classification 
for villous abnormalities is now widely used for 
assessing the severity of villous atrophy in clinical 
practice. While the histological changes seen in 
celiac disease are considered to be characteristic, 
they are not pathognomonic, as similar changes 
can be seen in several other conditions, including 
tropical sprue, parasitic infection, common variable 
LPPXQRGH¿FLHQF\ KXPDQ LPPXQRGH¿FLHQF\ YLUXV
(HIV) enteropathy, and drug and enteropathy induced 
by food allergy (such as to cow’s milk). Four to six 
biopsy samples must be taken from the second part 
of the duodenum, and from the duodenal bulb. In 
patients with ultrashort celiac disease, pathology may 
EHFRQ¿QHGWRWKHGXRGHQDOEXOE²KLJKOLJKWLQJWKH
importance of taking biopsies from that area. Biopsies 
must be taken when patients are on a gluten-containing 
diet (at least 3 g of gluten/day for 2 weeks). 
Under light microscopy, the most characteristic 
KLVWRORJLFDO ¿QGLQJV LQ SDWLHQWVZLWK FHOLDF GLVHDVH
who are taking a gluten-containing diet includes 
increased density of intraepithelial lymphocytes 
(> 25/100 epithelial cells), crypt hyperplasia, with a 
decreased villi/crypt ratio, blunted or atrophic villi, 
PRQRQXFOHDUFHOOLQ¿OWUDWLRQLQWRWKHODPLQDSURSULDRU
epithelial changes, including structural abnormalities 
in epithelial cells.5
)LJXUH &ODVVLFDO VFDOORSLQJRI GXRGHQDOPXFRVDVHHQ LQ
&HOLDFGLVHDVHDWHQGRVFRS\8
7DEOH0RGL¿HG0DUVKFODVVL¿FDWLRQRIJOXWHQLQGXFHGVPDOO
LQWHVWLQDOGDPDJH5
Stage Description
Stage 0 3UHLQ¿OWUDWLYH PXFRVD XS WR  RI SDWLHQWV ZLWK
dermatitis  herpetiformis (DH) or gluten ataxia have 
small-intestinal biopsy specimens that appear normal.
Stage 1 Increase in the number of intraepithelial lymphocytes 
(IELs) to more than 25 per 100 enterocytes with a 
normal crypt/villi ratio.
Stage 2 Crypt hyperplasia. In addition to the increased IELs, 
there is an increase in crypt depth without a reduction 
in villus height
Stage 3 Villous effacement. This is the classic celiac disease 
lesion. It is found in 40% of DH patients. Despite marked 
mucosal changes, many individuals are asymptomatic 
DQG DUH WKHUHIRUH FODVVL¿HG DV KDYLQJ VXEFOLQLFDO RU
silent celiac disease. This lesion is characteristic, but 
not pathognomonic, of celiac disease and can also 
be seen with severe giardiasis, infantile food allergy, 
or post-enteritis syndrome, graft-versus-host disease, 
chronic ischemia of the small intestine, tropical sprue, 
LPPXQRJOREXOLQ GH¿FLHQFLHV DQG RWKHU LPPXQH
GH¿FLHQFLHVDQGDOORJUDIWUHMHFWLRQ
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TREATMENT 
The only treatment for celiac disease, at present, 
is a strictly gluten-free diet for life. No foods or 
medications containing gluten from wheat, rye, or 
barley or their derivatives can be taken, as even small 
quantities of gluten may be harmful. The safe limit of 
gluten intake varies from patient to patient and has 
been considered to be 10–100 mg/day, although a 
subsequent study indicated that the upper limit should 
be no more than 50 mg/day. Approximately 70% of 
patients report an improvement in symptoms within 2 
weeks of starting the gluten-free diet.5,7,10–12
1215(63216,9($1'5()5$&725<&(/,$&
DISEASE
Non-responsive celiac disease (NRCD) can be 
GH¿QHG DV SHUVLVWHQW RU UHFXUUHQW V\PSWRPV VLJQV
RU ODERUDWRU\¿QGLQJV FRQVLVWHQWZLWK DFWLYH FHOLDF
disease, despite at least 12 months of treatment with 
the GFD.7 Meanwhile, refractory celiac disease 
(RCD) can be defined as persistent or recurrent 
small-intestinal villous atrophy with symptoms 
of malabsorption, despite 12 months or more of a 
strict GFD, in the absence of an overt lymphoma or 
another condition that causes villous atrophy. RCD 
is characterized by the absence (type I) or presence 
(type II) of an aberrant population of IELs that lack 
lineage differentiation surface markers (eg, CD4, 
CD8, or the interleukin-2 receptor) but are positive for 
cytoplasmic CD3, indicating a T-cell phenotype. The 
prognoses for patients with RCD I and for RCD II differ 
markedly. RCD I is associated with severe symptoms 
and malabsorption, but life expectancy is not greatly 
reduced; the disease often responds to treatment with 
topical steroids and enteric delivery of budesonide.5,7,13
&203/,&$7,21$1'352*126,6
Patients with (long-term untreated) celiac disease 
have an elevated risk for benign and malignant 
complications, and mortality. Cancer development 
has the highest risk in the initial years after diagnosis. 
Malignancy as complication of CD including 
malignant lymphomas, small-bowel adenocarcinoma, 
oropharyngeal tumors. Non-malignancy complication 
includes unexplained infertility, impaired bone health 
and growth (osteoporosis), bone fractures, and adverse 
pregnancy outcome.5
There are several meta-analysis concerning the 
risk of developing thyroid disease, kidney disease, 
venous thromboembolism, and obstetric complications 
in patients with celiac disease. Sun, et al, in their 
meta-analysis concluded that the prevalence of 
thyroid disease, especially euthyroidism autoimmune 
thyroid disease and hypothyroidism, in patients with 
CD is increased compared with that in controls, 
which suggests that CD patients should be screened 
for thyroid disease.14 Meanwhile, in meta-analysis 
conducted by Wijarnpreecha et al, demonstrated an 
increased risk of kidney diseases including diabetic 
nephropathy and IgA nephropathy among patients 
with CD.15 Venous thromboembolism also increased in 
SDWLHQWVZLWK&'&KURQLFLQÀDPPDWLRQZKLFKOHDGV
WRK\SHUFRDJXODEOHVWDWHDQGDOVRYLWDPLQGH¿FLHQFLHV
related to malnutrition has been postulated as the cause 
of this complication in meta-analysis conducted by 
Ungprasert et al.16 Finally, a meta-analysis conducted 
by Saccone et al, conclude that women with celiac 
GLVHDVHKDGDVLJQL¿FDQWO\KLJKHUULVNRIGHYHORSLQJ
obstetric complications including preterm birth, 
intrauterine growth restriction, stillbirth, low birth 
weight and small for gestational age.17
021,725,1*
&HOLDFGLVHDVHLVDOLIHORQJLQÀDPPDWRU\FRQGLWLRQ
that affects multiple organ systems, so patients should 
be followed up routinely. There are no differences in 
recommendations for monitoring symptomatic vs. 
asymptomatic patients. Based on expert consensus, 
at the time of diagnosis, patients should be evaluated 
for common co-existing autoimmune conditions, such 
DVWK\URLGDQGOLYHUGLVHDVHVDVZHOODVGH¿FLHQFLHV
in iron, vitamin D, and vitamin B12. There is general 
agreement among guidelines (Table 5) that patients 
VKRXOGEHH[DPLQHGDWOHDVWWZLFHLQWKHLU¿UVW\HDUDIWHU
diagnosis to monitor symptoms, dietary adherence, 
nutrition, body mass index, and serologic features.7
CONCLUSION
Celiac disease is a multisystem autoimmune 
disorder triggered by exposure to dietary gluten in 
genetically predisposed individuals and still pose as a 
problem for clinician. It is still one of the commonest, 
lifelong disorders affecting mankind all over the 
ZRUOG&KURQLF LQÀDPPDWLRQ FDXVHV HQWHURSDWK\ LQ
CD and associated with poor absorption of nutrients 
leading to malabsorption and an increase in morbidity 
and mortality. If not treated well, this condition can 
elevate risk for benign and malignant complication 
especially cancer, lymphomas, and other complication 
such as thyroid disease, kidney disease, venous 
thromboembolism, and obstetric problem. Diagnosis 
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of celiac disease consist of serology examination which 
includes anti-TG2 and EMA, genetic testing for HLA 
DQ2/DQ8, endoscopy and biopsy of the small bowel 
mucosa. The only treatment for celiac disease is a 
strict lifelong gluten-free diet. For nonresponsive or 
refractory disease topical steroid and enteric delivery 
of budesonide can be considered. Patients should be 
H[DPLQHGDWOHDVWWZLFHLQWKHLU¿UVW\HDUDIWHUGLDJQRVLV
to monitor symptoms, dietary adherence, nutrition, 
body mass index, and serologic features. Afterwards, 
routine follow up is needed to monitor adherence, and 
to detect complications due to this condition. 
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Table 5. Monitoring in Celiac Disease.7
Test Interval Comments
Clinical evaluation Annually or if 
recurrent symptoms 
Normal titers are insensitive for ongoing gluten exposure or enteropathy
Serology Every 3–6 months 
until normal, then 
every 1–2 years
3HUVLVWHQWO\LQFUHDVHGRULQFUHDVLQJWLWHUVLQGLFDWHVLJQL¿FDQWJOXWHQH[SRVXUH
Nutritional 
evaluation
Every 3–6 months 
until normal, then 
every 1–2 years
&RPPRQGH¿FLHQFLHVLQLURQ2+YLWDPLQ'YLWDPLQ%IRODWHDQG]LQF
0RQLWRUIRUZHLJKWJDLQORZ¿EHULQWDNHDQGFRQVWLSDWLRQ
Bone density 2QFHZLWKLQ¿UVW 
2 years
6LJQL¿FDQWLQFUHDVHVLQERQHGHQVLW\RIWHQDUHREVHUYHGLQWKH¿UVW\HDUDIWHUGLDJQRVLV
PDQ\H[SHUWVWKHUHIRUHDGYRFDWHWHVWLQJIRUWKH¿UVWWLPHDIWHU\HDURQWKH*)'
Liver 
transaminases 
levels
At diagnosis, then 
every 1–2 years
,QFUHDVHGOHYHOVRI$67DQG$/7DUHDFRPPRQPDQLIHVWDWLRQRIFHOLDFGLVHDVH3HUVLVWHQW
increases or increasing levels indicate a comorbid liver disorder
Thyroid function 
tests
At diagnosis, then 
every 1–2 years
Autoimmune thyroid disease is the most common comorbid autoimmune disorder, found 
in approximately 15–20% of adults with celiac disease
Duodenal biopsy Consider 1–2 years 
after diagnosis
5HSHDWHGELRSVLHVWRHYDOXDWHKHDOLQJIUHTXHQWO\DUHSHUIRUPHGKRZHYHULWLVQRWFOHDU
if this is necessary for patients with well-treated, clinically responsive celiac disease
Cancer screening As for general 
population
$OWKRXJKUDWHVRIFHUWDLQFDQFHUVDUHLQFUHDVHGWKHVHDUHQRWVXI¿FLHQWO\FRPPRQWR
ZDUUDQWGLVHDVHVSHFL¿FVFUHHQLQJ
